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Autism spectrum disorder (ASD) is a group of neurodevelopmental disorders involving
age-dependent gene dysregulation. Reelin is a glycoprotein that varies its expression
throughout lifetime and controls cortical patterning and synaptogenesis. Brain and plasma
reelin levels have been reported to be low in adults with autism; as well as in children with
autism, but only when compared to control adults. Therefore, reelin expression levels in
children with autism are unclear. For this reason, we compared plasma reelin levels in
children with autism and children without autism (non-ASD) of similar ages to evaluate
reelin expression in ASD during childhood. Plasma samples from 19 non-ASD (8.9 ± 0.8
years) and 40 children with autism (7.5 ± 0.5 years) were analyzed. We found that 50% of
the children with autism displayed similar plasma reelin levels to the non-ASD group.
However, the remaining 50% expressed more than 30 times more reelin compared to
non-ASD levels. We also show that male children with autism displayed significantly higher
reelin levels than females. The clinical presentation of this subgroup could not be
distinguished from that of children with autism. Epilepsy or attention-deficit/hyperactivity
disorder (ADHD) was not associated to reelin levels. We conclude that the high levels of
plasma reelin might be an important hallmark in a subset of children with autism, previously
unnoticed. As we could not find any correlation between reelin levels and ASD clinical
presentations, our results may indicate transient reelin increases in the plasma or the
characterization of a group of ASD individuals with a different pathophysiology.
Keywords: reelin, autism, children, enzyme-linked immunosorbent assay, Western blotting, dimers, oligomersINTRODUCTION
Autism spectrum disorder (ASD) is a heterogeneous group of neurodevelopmental disorders,
characterized by deficits in social interaction and communication, as well as a wide range of
stereotyped and repetitive behaviors. These characteristics are the basis of ASD diagnosis through
behavioral tests and observation of the patients phenotype (1). In Europe, the average age of
diagnosis of ASD is 3.5 years old, with great variability between countries. This is a fairly late age,g March 2020 | Volume 11 | Article 2421
Cuchillo-Ibáñez et al. High Reelin Levels in Autismgiven that some symptoms of ASD appear in the first year of
lifetime, and highlights the gap between diagnosis and possible
treatments (1).
A high proportion of the genes involved in ASD encode synaptic
proteins, which has led to suggestions that ASD is a disorder of
synaptogenesis (2, 3). One of these genes is RELN, which encodes
for reelin protein. The Autism Sequencing Consortium in De
Rubeis et al. (3) identified RELN with a 95% probability of being
a gene whose anomalies directly contribute to autism. Reelin is a
secreted signaling glycoprotein that regulates dendritic, axonal, and
synaptogenesis development (4). During brain development, reelin
controls neuronal migration and correct lamination in the
neocortex, hippocampus, cerebellum, and spinal cord (5). Reelin
function in non-neural tissues is not completely understood,
however it is found in plasma. The major sources of reelin in the
plasma are presumed to be the liver, platelets, and other
differentiated blood cells (6). Although the regulation of gene
expression is specific to each tissue, a parallelism has been
observed between the mechanisms of epigenetic regulation in
lymphocytes and the brain, including changes in methylation of
the promoter of genes specifically related to synaptic function (7).
In the unique study where reelin levels have been quantified
in plasma from individuals with autism (Table 1), reelin levels
were reported to be lower in ASD children with respect to those
in control adults, whereas no differences were found after
comparison with siblings of similar age (8). Therefore, since
ASD is a developmental disorder, it is important to examine
reelin levels in children of related age, to assess the trend of
potential changes in this protein before adulthood.Frontiers in Psychiatry | www.frontiersin.org 2MATERIALS AND METHODS
Patients and Interventions
The control/case study was designed with over 59 consecutive
patients of Caucasian ethnic background (Table 1), coming from
the neuropediatric outpatients’ clinic of a departmental university
hospital, and all evaluated by the same neuro-pediatric team
(Neuropediatric Unit, University Hospital of Sant Joan d’Alacant,
Pediatric Department, Spain). All children passed through standard
pediatric and neurological exams and needed routine blood
workups. From them, 40 patients met the criteria for different
ASD levels, following Diagnostic and Statistical Manual of Mental
Disorders, Fifth Edition (DSM-V) criteria (14). The diagnosis was
confirmed by a multidisciplinary team (pediatric neurologist, child
psychiatrist, neuropsychologist, and social worker), and only in
borderline cases, Autism Diagnostic Observation Schedule (ADOS
evaluation) was used to confirm the diagnosis. The other 19 subjects
did not meet any of the ASD criteria (named as non-ASD), but were
attended by other minor neuropediatric circumstances such as the
ones described below:
- Lobar benign infancy epilepsy (blood sample to test
biochemical parameters)
- Single febrile seizures (blood sample to test infectious disease)
- Borderline or mild mental retardation (blood sample to test
nutritional status).
- Migraine (blood sample to test iron status)
- Viral infections (blood sample to confirm biological markers in
blood)TABLE 1 | Reelin expression in ASD.




Control adults = 38 ± 15 y; n = 8
ASD children = 7 ± 2 y;
n = 13 twin pairs
Decrease Fatemi et al., (8)
Children Control siblings= 7 ± 3 y; n = 6
ASD children = 7 ± 2 y;
n = 13 twin pairs
No changes
Adults Control adults = 23 ± 4 y; n = 8
ASD adults = 25 ± 5 y; n = 5
Decrease
(only the 180-kDa fragment)
in cerebellum
Fatemi et al., (9)
Adults Control adults = 26 y; n = 10





Fatemi et al., (10)
Adults Control adults = 15-56 y; n = 11




Chow et al., (11)
Adults Control adults = 34 y; n = 10
ASD adults = 30 y; n = 10
Increased binding of MeCP2 to
RELN promoter in cerebellum
Zhubi et al., (12)
Adults Control adults = 22 y; n = 10




Lintas et al., (13)March 2020 | VolumThe table shows those reports where changes in reelin protein levels or reelin mRNA expression have been described in individuals with autism with respect to non-ASD subjects in different
tissues.
ASD, autism spectrum disorder.e 11 | Article 242
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around 9:00 am. The samples were collected in EDTA-containing
sterile tubes and centrifuged (1800×rpm, 10 min) generally in less
than 30 min after extraction. Plasma aliquots were stored at −80°
C until use. Anonymous handling of the samples by the basic
research unit was applied. This study was carried out in
accordance with the recommendations of the “Ethics
Committee” of the University Miguel Hernández de Elche and
approved (reference IN.ICI.01.17). All subjects gave written
informed consent in accordance with the Declaration of Helsinki.
Measurement of Reelin by Enzyme-Linked
Immunosorbent Assay
Commercial enzyme-linked immunosorbent assay (ELISA) kits
(SEC775Hu, Cusabio Technology Llc) were used to quantify
reelin in human plasma (50 µl of each plasma sample per well),
according to manufacturer´s instructions.
SDS-PAGE and Western Blotting
Plasma aliquots (1.5 µl) were boiled at 98°C for 3 min in 6×
Laemmli sample buffer. All samples were assayed in at least two
independent assays. After SDS-PAGE, the proteins were
transferred to 0.45 µm pore PVDF membranes and detected
with antibodies against reelin (N-terminal clone142, 1:400,
Merck Millipore, Billerica, MA, USA) and transferrin (1:3000,
Abcam, Cambridge, UK), which was used as a loading control.
Primary antibody binding was visualized with fluorescently
(IRDye) labeled secondary antibodies (1: 10000) and images
were acquired using an Odyssey CLx Infrared Imaging system
(LI-COR Biosciences GmbH).
Statistical Analysis
The distribution of data was tested for normality using a
D’Agostino-Pearson test. Data were analyzed and compared by
groups, gender, and comorbid conditions using unpaired
Student´s t test or Mann–Whitney test. For the correlation
between age and reelin values, the “Spearman r” was calculated.
The results are presented as the means ± SEM and all the analyses
were performed using GraphPad Prism (Version 7; GraphPad
Software, Inc). p value < 0.05 was considered significant.RESULTS
Reelin protein levels in plasma samples from children with
autism and non-ASD age-related children (Table 2) wereFrontiers in Psychiatry | www.frontiersin.org 3analyzed by ELISA assays (Figure 1). Reelin levels were higher
in children with autism (0.44 ± 0.03 ng/ml, n = 40) with respect
to those in non-ASD children (0.32 ± 0.03 ng/ml; n = 19; p <
0.01) When comparing by gender, no differences were found
between male and female children in overall. However, reelin
levels in males with autism were significantly higher (0.44 ± 0.03
ng/ml) than those in the male non-ASD group (0.30 ± 0.03 ng/
ml; p = 0.01), while no differences were found between female
children. No correlation was found between age and reelin levels,
although we observed a tendency of a positive correlation
between age and male children with autism (Pearson r = 0.31,
p = 0.053). Stratification by epilepsy or attention-deficit/
hyperactivity disorder (ADHD) (attention deficit hyperactivity
disorder) did not show statistical differences in reelin levels when
all children were analyzed.
We further analyzed plasma reelin levels by Western blot,
which allowed the quantification of the full-length reelin (420
kDa) and separately, the N-terminal proteolytic fragments
(Figure 2A). However, among these fragments, only the major
310-kDa fragment was clearly detected, not the 180-kDa
fragment. Full-length reelin levels were significantly higher in
children with autism (~17 times) with respect to non-ASD
children (p = 0.0028). When these reelin values were plotted, a
wide spread of reelin levels was observed in the ASD group. For
the analysis, a histogram of the frequency distribution of ASDTABLE 2 | Distribution by age and gender of children with autism and non-ASD children of this study.
Gender n Age (y) Age range (y) Age median (y) Epilepsy (n) ADHD (n)
Non-ASD Male 9 (47%) 9.40 ± 1.17 1.99–13.56 9.87 4 1
Female 10 (53%) 8.42 ± 1.29 2.43–14.69 9.76 3 0
All 19 8.88 ± 0.86 1.99–14.69 10.31 7 (37%) 1 (5.2%)
ASD Male 32 (80%) 7.42 ± 0.61 1.9–14.28 7.65 10 8
Female 8 (20%) 7.64 ± 1.46 2.78–14.52 7.94 7 1
All 40 7.47 ± 0.56 1.90–14.52 7.65 17 (42.5%) 9 (22.5%)March 2020 | Volume 11 |Age is expressed as mean [in years (y) ± SEM]. Cases with comorbid situations such as epilepsy and/or ADHD are displayed. Percentages are expressed respect to “All” in each group.FIGURE 1 | High reelin plasma levels in children with autism. Reelin from
plasma samples from age-related children with autism (n = 40) and non-ASD
(n = 19) was measured with a specific ELISA. Gender of the children is
indicated. Mann Whitney test, *p = 0.0056. ASD, autism spectrum disorder;
ELISA, enzyme-linked immunosorbent assay.Article 242
Cuchillo-Ibáñez et al. High Reelin Levels in Autismvalues was performed and two subgroups were distinguished
(Figure 2B). The first ASD subgroup (n = 20) displayed full-
length reelin levels which were not significantly different (105% ±
13%, range 16%–240%) to those found in the non-ASD group
after normalization (100% ± 10%, range 36%–178%). A second
ASD subgroup (n = 20) did not follow a normal distribution and
displayed higher full-length reelin levels than both the non-ASD
group and the first ASD subgroup (3275% ± 644%, range 290%–
10400%, p < 0.0001). In the non-ASD group, only 1 out of 19
children displayed high reelin levels of ~20 times higher than the
remaining cases. The 310-kDa reelin fragment levels did not
show significant differences between groups (Figure 2C).
Comparison of full-length reelin levels by gender revealed
higher levels in male children with autism with respect to females
with autism (~300% increment, p = 0.014), which is consistent
with the distribution of high full-length reelin levels by gender
(non-ASD cases: 1 out of 9 male children, no female children
with high reelin levels; ASD cases: 18 out of 33 male children, 1
out of 7 female children with high reelin levels). Correlation of
full-length reelin levels with age was not found, neither was any
association with epilepsy or ADHD.DISCUSSION
We have found that ~50% of the analyzed children with autism
expressed extremely high levels of reelin in blood (according to
Western blotting assays). The stratification of ASD cases
according to plasma reelin levels was independent of age or
any other comorbid conditions such as epilepsy, despite some
previous reports having found a correlation between this
disorder and reelin (15, 16). The only study so far reporting
measurements of reelin in plasma in ASD (8) showed differences
in reelin levels in children with autism as compared to control
adults, but not to their phenotypically normal age-matched
siblings and their parents, suggesting a familial variability of
reelin levels that is not associated with ASD. Furthermore,
although they also employed Western blot analysis to measureFrontiers in Psychiatry | www.frontiersin.org 4reelin levels, we believe the underlying reason behind this
discrepancy might be a degradation of reelin in their samples.
Their blots show the full-length reelin protein and two
proteolytic fragments (310 and 180 kDa). In our experience,
the presence of abundant levels of the 180-kDa fragment may be
a sign of reelin degradation in blood; whereas in brain extracts
this fragment is abundant (17). Reelin in human plasma is
sensitive to proteolysis, freeze-thawing and heating during
long-term storage (18, 19). Another complementary
explanation is that the notable differences we observed were
only seen in ~50% of the cases, representing an undefined subset
of children which might have been under-represented in the
previous study (8). A smaller sample size in the previous studies
in this area (Table 1) might therefore explain why the subjects
with high reelin levels were previously not observed.
In our study, male children with autism displayed higher
levels of reelin than females with autism, analyzed by ELISA and
by Western blot. Little is known about the gender dimorphic
expression of reelin, but some mice models show gender-
associated reelin expression and more vulnerability to reelin
expression changes in males (20, 21). Specific hormones could
be candidates as regulators of reelin expression, such as the sex
hormones testosterone and estrogen, which have been reported
to modulate expression of RELN (22, 23). The neuropeptides
oxytocin and vasopressin, whose effects on brain and behavior
are sexually dimorphic, especially during the course of
development, have been implicated in autism and are likely
involved in reelin expression regulation (23).
Whole-genome analysis of cortex mRNA levels has revealed
age-dependent dysregulation of specific pathways. In children
with autism (2–14 years), genetic pathways regulating cortical
patterning, cell number and differentiation are dysregulated,
whereas in adults with autism (15–56 years), dysregulation
affects signalling, and repair pathways (11). In adults with
autism, reelin expression is lower in prefrontal cortex, frontal
cortex, temporal cortex, and cerebellum [(11, 15, 17, 18),
Table 1]. Thus, it would be important to determine if these
increments in plasma reelin levels represent a transientA
B
C
FIGURE 2 | Two subgroups among the ASD subjects are defined with respect to plasma full-length reelin levels. (A) Representative Western blot of plasma reelin
and transferrin (loading control) from children with autism and non-ASD children. Arrows indicate the full-length protein (420 kDa), the 310-kDa N-terminal fragment,
and the faint 180-kDa fragment. (B) Quantification of full-length reelin intensity normalized with respect to transferrin, represented using a broken y-axis due to a large
data spread (n = 40 children with autism, n = 19 non-ASD children). Mann–Whitney test, *p < 0.0001, “high ASD reelin” vs “normal ASD reelin” and “high ASD reelin”
vs “non-ASD reelin.”(C) Quantification of the 310-kDa reelin fragment intensity, normalized respect to transferrin (n = 40 children with autism, n = 19 non-ASD
children). Gender of the children is indicated. Mean of the values are represented as horizontal lines.March 2020 | Volume 11 | Article 242
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controlled by reversible mechanisms, such as epigenetic
regulation. Accordingly, the epigenetic regulation of RELN
varies throughout development, in particular, methylation of
RELN promoter in the temporal cortex shows little methylation
before puberty (allowing protein expression), in contrast to a
strong post-pubertal methylation which reduces expression of
reelin (12, 13). Furthermore, methylation of the RELN promoter
in the peripheral blood was reported to be different in male and
female individuals (24). In our study, reelin levels only frommale
children with autism tended to increase with age, suggesting the
possibility of a different epigenetic mechanism with respect to
female children with autism, and likely with respect to non-ASD
children as well. Overall, our data strongly suggests a gender
dimorphic expression of reelin in ASD, where increased reelin
levels in males would be associated with ASD. Further studies
including larger number of subjects are required to confirm this
gender-associated trend.
Single nucleotide polymorphisms (SNPs) in RELN have been
significantly associated with an increased risk of ASD (25) as well
as de novo mutations in RELN with a high probability of being
pathological (26, 27). It would be interesting to determine
whether the children with autism and high reelin levels of this
study carry RELN variants that affect its expression, and to test
whether these children express other variants affecting genes in
the reelin pathway.
We found greater differences between non-ASD children and
children with autism and when reelin expression levels, from the
same samples, were measured byWestern blot than when they were
evaluated by ELISA.While in the denaturing-conditions ofWestern
blot reelin monomers were analyzed, the ELISA assay was likely
measuring native reelin homodimers, the active form of reelin that
binds to the receptors (28). Therefore, the fact that children with
autism display a large increase in reelin monomers levels after
denaturation suggests the existence of a higher proportion of reelin
dimers/oligomers in the plasma of these children with regards to
non-ASD children. Differences in reelin complexes have been
reported in other neurological condition such as Alzheimer’s
disease (29, 30). Remarkably, recent data indicate that commercial
anti-reelin antibodies display different reactivity to monomeric or
dimeric reelin protein (31), which highlights the relevance of an
appropriate methodological design for reelin quantitative analyses.
Our results raise new questions about the physiological
relevance of high reelin expression in ASD at early lifetime. It
would be important to confirm whether children with high reelin
levels develop different ASD clinical presentations later on, since
reelin function is related to migration and synaptogenesis
development and such mechanisms have been found to be
dysregulated in ASD (32, 33). This scenario might indicate that
altered reelin plasma levels could contribute to the progression
and severity of the disease during childhood.
Children in this study were younger than 15 years old and
belonged to a “compulsory referral population” of 33,731 children.
This population includes all the children belonging to our regional
health department and also covers refugees or migrants, who are
registered in the database with free health assistance. We thereforeFrontiers in Psychiatry | www.frontiersin.org 5believe our results to be of epidemiological relevance as our dataset
represents 1.07% of the estimated 363 autistic children in our
regional catchment area. Nevertheless, given the preliminary
nature of this study, our next aim will focus on replicating this
study in other cohorts as well as in the comparison to a group
without neurological disorders, as typically developing children.DATA AVAILABILITY STATEMENT
The datasets for this article are not publicly available because
participants recruited in this study did not give their consent to
their raw data being publicly shared even if anonymised.
Additional information regarding the datasets should be
directed to icuchillo@umh.es.ETHICS STATEMENT
The studies involving human participants were reviewed and
approved by Ethic Committee from "Órgano Evaluador de
Proyectos" of "Vicerrectorado de Investigación e Innovación"
of "Universidad Miguel Hernández de Elche". Written informed
consent to participate in this study was provided by the
participants' legal guardian/next of kin, in accordance with the
Declaration of Helsinki.AUTHOR CONTRIBUTIONS
IC-I, JS-V and FC-M designed the study, performed the
experiments and the analysis and wrote the manuscript. PA-L,
LP-F and FC-M evaluated the children and performed the
pediatric and neurological exams.FUNDING
This work was supported by grants from Fondo de
Investigaciones Sanitarias (PI15/00665 and PI19-01359, co-
funded by the Fondo Europeo de Desarrollo Regional, FEDER
"Investing in your future"), by the Direcció General d’Universitat,
Investigació i Ciència, GVA (AICO/2018/090) and through
CIBERNED (Instituto de Salud Carlos III, Spain). We also
acknowledge financial support from the Spanish Ministerio de
Economía y Competitividad, through the “Severo Ochoa”
Programme for Centres of Excellence in R&D (SEV-2017-0723).ACKNOWLEDGMENTS
We want to acknowledge the dedicated and cared work of Ms
Sonia Antón-Aliaga and Silvia Crespo-Campos, special ASD
nursing team, from the Day Hospital Unit, Paediatric
Department, University Hospital of Sant Joan d’Alacant. We
also want to acknowledge the Special team in Diagnostic and
Management of the ASD patients in our Department (AITEA),
University Hospital of Sant Joan d’Alacant.March 2020 | Volume 11 | Article 242
Cuchillo-Ibáñez et al. High Reelin Levels in AutismREFERENCES
1. Magán-Maganto M, Bejarano-Martín Á, Fernández-Alvarez C, Narzisi A,
García-Primo P, Kawa R, et al. Early Detection and Intervention of ASD: A
European Overview. Brain Sci (2017) 7:159. doi: 10.3390/brainsci7120159
2. Pinto D, Delaby E, Merico D, Barbosa M, Merikangas A, Klei L, et al.
Convergence of genes and cellular pathways dysregulated in autism spectrum
disorders. Am J Hum Genet (2014) 94:677–94. doi: 10.1016/j.ajhg.2014.03.018
3. De Rubeis S, He X, Goldberg AP, Poultney CS, Samocha K, Ercument Cicek
A, et al. Synaptic, transcriptional and chromatin genes disrupted in autism.
Nature (2014) 515:209–15. doi: 10.1038/nature13772
4. Wasser CR, Herz J. Reelin: Neurodevelopmental Architect and Homeostatic
Regulator of Excitatory Synapses. J Biol Chem (2017) 292:1330–8.
doi: 10.1074/jbc.R116.766782
5. Herz J, Chen Y. Reelin, lipoprotein receptors and synaptic plasticity. Nat Rev
Neurosci (2006) 7:850–9. doi: 10.1038/nrn2009
6. Khialeeva E, Carpenter EM. Nonneuronal roles for the reelin signaling
pathway. Dev Dyn (2017) 246:217–26. doi: 10.1002/dvdy.24462
7. Davies MN, Volta M, Pidsley R, Lunnon K, Dixit A, Lovestone S, et al.
Functional annotation of the human brain methylome identifies tissue-
specific epigenetic variation across brain and blood. Genome Biol (2012) 13:
R43. doi: 10.1186/gb-2012-13-6-r43
8. Fatemi SH, Stary JM, Egan EA. Reduced blood levels of reelin as a
vulnerability factor in pathophysiology of autistic disorder. Cell Mol
Neurobiol (2002) 22:139–52. doi: 10.1023/A:1019857620251
9. Fatemi SH, Snow AV, Stary JM, Araghi-Niknam M, Reutiman TJ, Lee S, et al.
Reelin signaling is impaired in autism. Biol Psychiatry (2005) 57:777–87.
doi: 10.1016/j.biopsych.2004.12.018
10. Fatemi SH, Stary JM, Halt AR, Realmuto GR. Dysregulation of Reelin and Bcl-
2 proteins in autistic cerebellum. J Autism Dev Disord (2001) 31:529–:35. doi:
10.1023/A:1013234708757
11. Chow ML, Pramparo T, Winn ME, Barnes CC, Li H-R, Weiss L, et al. Age-
Dependent Brain Gene Expression and Copy Number Anomalies in Autism
Suggest Distinct Pathological Processes at Young Versus Mature Ages. PloS
Genet (2012) 8:e1002592. doi: 10.1371/journal.pgen.1002592
12. Zhubi A, Chen Y, Dong E, Cook EH, Guidotti A, Grayson DR. Increased
binding of MeCP2 to the GAD1 and RELN promoters may be mediated by an
enrichment of 5-hmC in autism spectrum disorder (ASD) cerebellum. Transl
Psychiatry (2014) 4:e349. doi: 10.1038/tp.2013.123
13. Lintas C, Sacco R, Persico AM. Differential methylation at the RELN gene
promoter in temporal cortex from autistic and typically developing post-
puberal subjects. J Neurodev Disord (2016) 8:18. doi: 10.1186/s11689-016-
9151-z
14. American Psychiatric Association. (2013).Diagnostic and statistical manual of
mental disorders, 5th Edition. Washington, DC: The American Psychiatric
Association. (2013). doi: 10.1176/appi.books.9780890425596
15. Tinnes S, Schäfer MKE, Flubacher A, Münzner G, Frotscher M, Haas CA.
Epileptiform activity interferes with proteolytic processing of Reelin required
for dentate granule cell positioning. FASEB J (2011) 25:1002–13. doi: 10.1096/
fj.10-168294
16. Haas CA, Dudeck O, Kirsch M, Huszka C, Kann G, Pollak S, et al. Role for
reelin in the development of granule cell dispersion in temporal lobe epilepsy.
J Neurosci (2002) 22:5797–802. doi: 10.1523/jneurosci.22-14-05797.2002
17. Cuchillo-Ibañez I, Mata-Balaguer T, Balmaceda V, Arranz JJ, Nimpf J, Sáez-
Valero J. The b-amyloid peptide compromises Reelin signaling in Alzheimer’s
disease. Sci Rep (2016a) 6:31646. doi: 10.1038/srep31646
18. Botella-López A, Burgaya F, Gavín R, García-Ayllón MS, Gómez-Tortosa E,
Peña-Casanova J, et al. Reelin expression and glycosylation patterns are
altered in Alzheimer’s disease. Proc Natl Acad Sci U S A (2006) 103:5573–8.
doi: 10.1073/pnas.0601279103Frontiers in Psychiatry | www.frontiersin.org 619. Lugli G, Krueger JM, Davis JM, Persico AM, Keller F, Smalheiser NR.
Methodological factors influencing measurement and processing of plasma
reelin in humans. BMC Biochem (2003) 4:9. doi: 10.1186/1471-2091-4-9
20. Palladino G, Nicolia V, Kovacs GG, Canterini S, Ciraci V, Fuso A, et al.
Sexually Dimorphic Expression of Reelin in the Brain of a Mouse Model of
Alzheimer Disease. J Mol Neurosci (2017) 61:359–67. doi: 10.1007/s12031-
016-0865-x
21. Hadj-Sahraoui N, Frédéric F, Delhaye-Bouchaud N, Mariani J. Gender Effect
on Purkinje Cell Loss in the Cerebellum of the Heterozygous Reeler Mouse. J
Neurogenet (1996) 11:45–58. doi: 10.3109/01677069609107062
22. Lammert DB, Howell BW. RELN Mutations in Autism Spectrum Disorder.
Front Cell Neurosci (2016) 10:84. doi: 10.3389/fncel.2016.00084
23. Carter CS. Sex differences in oxytocin and vasopressin: implications for autism
spectrum disorders? Behav Brain Res (2007) 176:170–86. doi: 10.1016/
j.bbr.2006.08.025
24. Nabil Fikri RM, Norlelawati AT, Nour El-Huda AR, Hanisah MN, Kartini A,
Norsidah K, et al. Reelin (RELN) DNA methylation in the peripheral blood of
schizophrenia. J Psychiatr Res (2017) 88:28–37. doi: 10.1016/j.jpsychires.2016.12.020
25. Wang Z, Hong Y, Zou L, Zhong R, Zhu B, Shen N, et al. Reelin gene variants
and risk of autism spectrum disorders: an integrated meta-analysis. Am J Med
Genet B Neuropsychiatr Genet (2014) 165B:192–200. doi: 10.1002/
ajmg.b.32222
26. Yuen RKC, Thiruvahindrapuram B, Merico D, Walker S, Tammimies K,
Hoang N, et al. Whole-genome sequencing of quartet families with autism
spectrum disorder. Nat Med (2015) 21:185–91. doi: 10.1038/nm.3792
27. Stessman HAF, Xiong B, Coe BP, Wang T, Hoekzema K, Fenckova M, et al.
Targeted sequencing identifies 91 neurodevelopmental-disorder risk genes
with autism and developmental-disability biases. Nat Genet (2017) 49:515–26.
doi: 10.1038/ng.3792
28. Kubo K, Mikoshiba K, Nakajima K. Secreted Reelin molecules form
homodimers. Neurosci Res (2002) 43:381–8. doi: 10.1016/S0168-0102(02)
00068-8
29. Cuchillo-Ibañez I, Balmaceda V, Mata-Balaguer T, Lopez-Font I, Sáez-Valero
J. Reelin in Alzheimer’s Disease, Increased Levels but Impaired Signaling:
When More is Less. J Alzheimer’s Dis (2016b) 52:403–16. doi: 10.3233/JAD-
151193
30. Cuchillo-Ibáñez I, Balmaceda V, Botella-López A, Rabano A, Avila J, Sáez-
Valero J. Beta-amyloid impairs reelin signaling. PloS One (2013) 8:e72297.
doi: 10.1371/journal.pone.0072297
31. Ishii K, Kohno T, Hattori M. Differential binding of anti-Reelin monoclonal
antibodies reveals the characteristics of Reelin protein under various
conditions. Biochem Biophys Res Commun (2019) 514:815–20. doi: 10.1016/
j.bbrc.2019.05.005
32. Belmonte MK, Allen G, Beckel-Mitchener A, Boulanger LM, Carper RA,
Webb SJ. Autism and abnormal development of brain connectivity. J Neurosci
(2004) 24:9228–31. doi: 10.1523/JNEUROSCI.3340-04.2004
33. de la Torre-Ubieta L, Won H, Stein JL, Geschwind DH. Advancing the
understanding of autism disease mechanisms through genetics. Nat Med
(2016) 22:345–61. doi: 10.1038/nm.4071
Conflict of Interest: The authors declare that the research was conducted in the
absence of any commercial or financial relationships that could be construed as a
potential conflict of interest.
Copyright © 2020 Cuchillo-Ibáñez, Andreo-Lillo, Pastor-Ferrándiz, Carratalá-Marco
and Sáez-Valero. This is an open-access article distributed under the terms of the
Creative Commons Attribution License (CC BY). The use, distribution or
reproduction in other forums is permitted, provided the original author(s) and the
copyright owner(s) are credited and that the original publication in this journal is
cited, in accordance with accepted academic practice. No use, distribution or
reproduction is permitted which does not comply with these terms.March 2020 | Volume 11 | Article 242
